Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of oral ecnoglutide in adults with overweight or obesity
CTR20262705Phase 2Active
- Sponsor
- Sciwind Biosciences
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of ecnoglutide in obesity, Overweight, sponsored by Sciwind Biosciences. Started Jul 2026; status: active.
02
Drugs
ecnoglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20262705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262705.